1.065

4.05% -0.045

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $1.065, with a volume of 448.15K. It is down -4.05% in the last 24 hours and down -4.05% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Previous Close:

$1.11

Open:

$1.08

24h Volume:

448.15K

Relative Volume:

0.32

Market Cap:

$251.53M

Revenue:

Net Income/Loss:

$-179.82M

P/E Ratio:

-0.8008

EPS:

-1.33

Net Cash Flow:

$-159.16M

1W Performance:

+7.19%

1M Performance:

-4.05%

6M Performance:

+31.14%

1Y Performance:

+22.41%

1-Day Range:

$1.02

$1.09

1-Week Range:

$0.93

$1.20

52-Week Range:

$0.4993

$1.60

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(858) 922-0718

Address

3013 SCIENCE PARK, SAN DIEGO, CA

Employee

135

Twitter

@GossamerBio

Next Earnings Date

2024-11-07

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	1.065	251.53M	0	-179.82M	-159.16M	-1.33
VRTX Vertex Pharmaceuticals Inc	474.31	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.13	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	651.13	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.76	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.68	28.75B	3.30B	-501.07M	1.03B	-2.1146

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

11:40 AM

GOSS Stock Sees Surge of Approximately 15.18% in Last Five Days - Knox Daily

11:40 AM

07:00 AM

Gossamer Bio Inc (NASDAQ: GOSS) Stock Gained 1.83% Over A Month – Any Room To Run? - Marketing Sentinel

07:00 AM

03:03 AM

Gossamer Bio showcases seralutinib studies at PVRI Congress - MSN

03:03 AM

Feb 06, 2025

Are Smart Investors Making the Right Decision? Gossamer Bio Inc (GOSS) - SETE News

Feb 06, 2025